155 related articles for article (PubMed ID: 2144467)
1. Demonstration of a splenic cytotoxic effector cell in mice of genotype SCID/SCID.BG/BG.
MacDougall JR; Croy BA; Chapeau C; Clark DA
Cell Immunol; 1990 Oct; 130(1):106-17. PubMed ID: 2144467
[TBL] [Abstract][Full Text] [Related]
2. Effector and precursor phenotypes of lymphokine-activated killer cells in mice with severe combined immunodeficiency (scid) and athymic (nude) mice.
Hasui M; Saikawa Y; Miura M; Takano N; Ueno Y; Yachie A; Miyawaki T; Taniguchi N
Cell Immunol; 1989 Apr; 120(1):230-9. PubMed ID: 2784720
[TBL] [Abstract][Full Text] [Related]
3. Analysis of the murine lymphokine-activated killer (LAK) cell phenomenon: dissection of effectors and progenitors into NK- and T-like cells.
Kalland T; Belfrage H; Bhiladvala P; Hedlund G
J Immunol; 1987 Jun; 138(11):3640-5. PubMed ID: 3495566
[TBL] [Abstract][Full Text] [Related]
4. Natural killer (NK) cells are present in mice with severe combined immunodeficiency (scid).
Dorshkind K; Pollack SB; Bosma MJ; Phillips RA
J Immunol; 1985 Jun; 134(6):3798-801. PubMed ID: 3989296
[TBL] [Abstract][Full Text] [Related]
5. Lymphokine-activated killer cells in mouse bone marrow chimaeras. The relationship to natural killer cells and to alloreactive cytotoxic T cells.
Sihvola M
Scand J Immunol; 1985 Nov; 22(5):479-88. PubMed ID: 2867599
[TBL] [Abstract][Full Text] [Related]
6. Murine lymphokine-activated killer (LAK) cells: phenotypic characterization of the precursor and effector cells.
Yang JC; Mulé JJ; Rosenberg SA
J Immunol; 1986 Jul; 137(2):715-22. PubMed ID: 2873187
[TBL] [Abstract][Full Text] [Related]
7. Natural killer cells in the thymus. Studies in mice with severe combined immune deficiency.
Garni-Wagner BA; Witte PL; Tutt MM; Kuziel WA; Tucker PW; Bennett M; Kumar V
J Immunol; 1990 Feb; 144(3):796-803. PubMed ID: 2136898
[TBL] [Abstract][Full Text] [Related]
8. Similarities and distinctions between murine natural killer cells and lymphokine-activated killer cells.
Merluzzi VJ; Smith MD; Last-Barney K
Cell Immunol; 1986 Jul; 100(2):563-9. PubMed ID: 3489533
[TBL] [Abstract][Full Text] [Related]
9. Lymphokine-activated killer cells and aging in mice: significance for defining the precursor cell.
Kawakami K; Bloom ET
Mech Ageing Dev; 1987 Dec; 41(3):229-40. PubMed ID: 2892985
[TBL] [Abstract][Full Text] [Related]
10. Further characterization of murine bone marrow-derived natural suppressor cells. Potential relationships between NS and NK/LAK activities.
Saffran DC; Singhal SK
Cell Immunol; 1990 Jun; 128(1):301-13. PubMed ID: 2140533
[TBL] [Abstract][Full Text] [Related]
11. Recombinant interleukin 2 allows the differentiation of Thy 1.2+ LAK cells from nude mouse spleen cells.
Nishimura T; Yagi H; Uchiyama Y; Hashimoto Y
Immunol Lett; 1986 Mar; 12(2-3):77-82. PubMed ID: 2873098
[TBL] [Abstract][Full Text] [Related]
12. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
Kawase I; Komuta K; Hara H; Inoue T; Hosoe S; Ikeda T; Shirasaka T; Yokota S; Tanio Y; Masuno T
Cancer Res; 1988 Mar; 48(5):1173-9. PubMed ID: 3257715
[TBL] [Abstract][Full Text] [Related]
13. Generation and characterization of purified adherent lymphokine-activated killer cells in mice.
Gunji Y; Vujanovic NL; Hiserodt JC; Herberman RB; Gorelik E
J Immunol; 1989 Mar; 142(5):1748-54. PubMed ID: 2783950
[TBL] [Abstract][Full Text] [Related]
14. Mouse tumors are heterogeneous in their susceptibility to syngeneic lymphokine-activated killer cells and delineate functional subsets in such effectors.
Sensi M; Grazioli L; Rodolfo M; Parmiani G
Cancer Immunol Immunother; 1990; 31(1):37-43. PubMed ID: 2306754
[TBL] [Abstract][Full Text] [Related]
15. Antibody-dependent cellular cytotoxicity mediated by murine lymphocytes activated in recombinant interleukin 2.
Shiloni E; Eisenthal A; Sachs D; Rosenberg SA
J Immunol; 1987 Mar; 138(6):1992-8. PubMed ID: 3493293
[TBL] [Abstract][Full Text] [Related]
16. Heterogeneity of lymphokine-activated killer cells induced by IL-2. Separate lymphoid subpopulations lyse tumor, allogeneic blasts, and modified syngeneic blasts.
LeFor AT; Eisenthal A; Rosenberg SA
J Immunol; 1988 Jun; 140(11):4062-9. PubMed ID: 3259603
[TBL] [Abstract][Full Text] [Related]
17. In vivo activation of natural killer cells and priming of IL-2 responsive cytolytic cells by loxoribine (7-allyl-8-oxoguanosine).
Pope BL; Chourmouzis E; Sigindere J; MacIntyre JP; Capetola RJ; Lau CY
Cell Immunol; 1993 Apr; 147(2):302-12. PubMed ID: 8453674
[TBL] [Abstract][Full Text] [Related]
18. In vivo boosting of lung natural killer and lymphokine-activated killer cell activity by interleukin-2: comparison of systemic, intrapleural and inhalation routes.
Flexman JP; Manning LS; Robinson BW
Clin Exp Immunol; 1990 Oct; 82(1):151-6. PubMed ID: 2208789
[TBL] [Abstract][Full Text] [Related]
19. Growth of MCF-7 human breast carcinoma in severe combined immunodeficient mice: growth suppression by recombinant interleukin-2 treatment and role of lymphokine-activated killer cells.
Zhai YF; Esselman WJ; Oakley CS; Chang CC; Welsch CW
Cancer Immunol Immunother; 1992; 35(4):237-45. PubMed ID: 1511458
[TBL] [Abstract][Full Text] [Related]
20. IL-4-induced lymphokine-activated killer cells. Lytic activity is mediated by phenotypically distinct natural killer-like and T cell-like large granular lymphocytes.
Peace DJ; Kern DE; Schultz KR; Greenberg PD; Cheever MA
J Immunol; 1988 May; 140(10):3679-85. PubMed ID: 2896213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
